Latest news
25 items- INSIDERSEC Form 3 filed by new insider Maher Illya Keith3 - Avalo Therapeutics, Inc. (0001534120) (Issuer)
- SECCerecor Inc. filed SEC Form 8-K: Leadership Update8-K - Avalo Therapeutics, Inc. (0001534120) (Filer)
- 13D/GSEC Form SC 13D/A filed by Cerecor Inc. (Amendment)SC 13D/A - Avalo Therapeutics, Inc. (0001534120) (Subject)
- INSIDERSEC Form 4 filed by Bruhn Suzanne Louise4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)
- INSIDERSEC Form 4 filed by Gutry Phil4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)
- INSIDERSEC Form 4 filed by Miller Joseph M4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)
- INSIDERSEC Form 4 filed by Persson Magnus4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)
- INSIDERSEC Form 4 filed by Kaplan Gilla4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)
- INSIDERSEC Form 4 filed by Cola Michael F4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)
- 13D/GSEC Form SC 13G filed by Cerecor Inc.SC 13G - Avalo Therapeutics, Inc. (0001534120) (Subject)
- 13D/GSEC Form SC 13D/A filed by Cerecor Inc. (Amendment)SC 13D/A - Avalo Therapeutics, Inc. (0001534120) (Subject)
- INSIDERSEC Form 4: Armistice Capital, Llc bought $12,557,902 worth of Common Stock (5,700,000 units at $2.20)4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)
- SECCerecor Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits8-K - Avalo Therapeutics, Inc. (0001534120) (Filer)
- SECSEC Form 424B5 filed by Cerecor Inc.424B5 - Avalo Therapeutics, Inc. (0001534120) (Filer)
- SECSEC Form 424B5 filed by Cerecor Inc.424B5 - Avalo Therapeutics, Inc. (0001534120) (Filer)
- SECCerecor Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Avalo Therapeutics, Inc. (0001534120) (Filer)
- SECCerecor Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits8-K - Avalo Therapeutics, Inc. (0001534120) (Filer)
- PRAvalo Therapeutics, Inc. Announces Corporate Name Change from Cerecor Inc.Name change underscores the Company's transition to developing innovative targeted therapies in immunology, immuno-oncology, and rare genetic diseasesRobust pipeline of six product candidates advancing in development with eight ongoing clinical programsFour therapies with Rare Pediatric Disease Designation with each potentially eligible for a Priority Review Voucher upon approvalMultiple data readouts anticipated in the second half of 2021 WAYNE, Pa. and ROCKVILLE, Md., Aug. 26, 2021 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a leading clinical-stage precision medicine company that discovers, develops, and commercializes targeted therapeutics for patients with significa
- INSIDERSEC Form 4 filed by Cerecor Inc.4 - Cerecor Inc. (0001534120) (Issuer)
- INSIDERSEC Form 4: ARMISTICE CAPITAL, LLC bought $408,515 worth of Common Stock (150,000 units at $2.72)4 - Cerecor Inc. (0001534120) (Issuer)
- SECCerecor Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Cerecor Inc. (0001534120) (Filer)
- PRCerecor Reports Second Quarter 2021 Financial Results and Provides Business UpdatesAnnounced positive results for low-dose cohort of CERC-002 (1.0 mg/kg) in moderate-to-severe Crohn's disease patients who had previously failed three or more lines of biologic therapies, including anti-TNF alpha treatmentsAnnounced plans to explore CERC-002 in patients with moderate-to-severe ulcerative colitis refractory to anti-TNF alpha therapiesCompleted $35 million debt financing that extends cash runway and supports multiple clinical catalysts anticipated in the second half of 2021 ROCKVILLE, Md. and CHESTERBROOK, Pa., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ:CERC), a biopharmaceutical company focused on becoming a leader in the development and commercialization of tre
- PRCerecor Announces Drawdown of $10 Million Tranche under its Debt Financing Agreement with Horizon Technology FinanceROCKVILLE, Md. and CHESTERBROOK, Pa., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ:CERC), a biopharmaceutical company focused on becoming a leader in the development and commercialization of treatments for immunologic, immuno-oncologic and rare genetic disorders, today announced that it has completed its second drawdown of $10 million under its previously announced $35 million debt financing agreement with Horizon Technology Finance Corporation (NASDAQ:HRZN) ("Horizon"). This second tranche was made available in connection with the Company's successful positive initial results from a Phase 1b proof-of-concept study evaluating CERC-002, an investigational first-in-class fully huma
- SECCerecor Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - Cerecor Inc. (0001534120) (Filer)
- PRCerecor Announces Positive Initial Phase 1b Results for CERC-002 in Moderate to Severe Crohn's Disease PatientsPositive results for low-dose cohort of CERC-002 (1.0 mg/kg) in moderate to severe Crohn's disease patients who had previously failed three or more lines of biologic therapies, including anti-TNF alpha treatmentsMean reduction in LIGHT levels of approximately 80% compared to baseline signify a dramatic and rapid reduction of LIGHT levels correlating to the pharmacodynamic effect of CERC-002Clinically meaningful endoscopic improvement in 75% (3/4) of subjects, as determined by colonoscopy (SES-CD score)CERC-002 was well tolerated with no drug-related severe adverse eventsCohort 2 (3.0 mg/kg dose) fully enrolled; complete data anticipated in 2H21Promising initial results support expansion to p
CERC FAQ
6 questionsWhat does Cerecor Inc. do?
Cerecor Inc., a biopharmaceutical company, focuses on development and commercialization of treatments for rare and orphan diseases. The company develops monosaccharide therapies for the treatment of congenital disorders of glycosylation, such as CERC-801, CERC-802, and CERC-803. It is also involved in the developing of CERC-007, an anti-IL-18 monoclonal antibody for the treatment of adult onset stills disease and multiple myeloma, as well as for the treatment of systemic juvenile idiopathic arthritis; CERC-006, an oral mTORC1/2 inhibitor to treat complex lymphatic malformations; and CERC-002...Where does CERC stock trade?
Cerecor Inc. (CERC) is listed on NASDAQ.What sector and industry is CERC in?
Cerecor Inc. operates in the Health Care sector, Major Pharmaceuticals industry.When did Cerecor Inc. go public?
Cerecor Inc. (CERC) completed its IPO in 2015.What companies are similar to CERC?
Notable peers in the same industry include PVAC (Penn Virginia Corporation), HGEN (Humanigen Inc.), NBSE (NeuBase Therapeutics Inc.). Compare CERC side-by-side with any of them on Quantisnow.How can I track CERC on Quantisnow?
Quantisnow aggregates Cerecor Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CERC to receive live email and push alerts on every new disclosure.